全文获取类型
收费全文 | 19586篇 |
免费 | 1060篇 |
国内免费 | 172篇 |
专业分类
耳鼻咽喉 | 182篇 |
儿科学 | 484篇 |
妇产科学 | 297篇 |
基础医学 | 2367篇 |
口腔科学 | 489篇 |
临床医学 | 1217篇 |
内科学 | 5178篇 |
皮肤病学 | 463篇 |
神经病学 | 1193篇 |
特种医学 | 866篇 |
外科学 | 3436篇 |
综合类 | 49篇 |
预防医学 | 415篇 |
眼科学 | 289篇 |
药学 | 1262篇 |
中国医学 | 34篇 |
肿瘤学 | 2597篇 |
出版年
2023年 | 126篇 |
2022年 | 66篇 |
2021年 | 488篇 |
2020年 | 319篇 |
2019年 | 381篇 |
2018年 | 512篇 |
2017年 | 415篇 |
2016年 | 514篇 |
2015年 | 501篇 |
2014年 | 621篇 |
2013年 | 810篇 |
2012年 | 1133篇 |
2011年 | 1340篇 |
2010年 | 720篇 |
2009年 | 614篇 |
2008年 | 1131篇 |
2007年 | 1300篇 |
2006年 | 1179篇 |
2005年 | 1210篇 |
2004年 | 1220篇 |
2003年 | 1128篇 |
2002年 | 1149篇 |
2001年 | 325篇 |
2000年 | 316篇 |
1999年 | 307篇 |
1998年 | 267篇 |
1997年 | 192篇 |
1996年 | 191篇 |
1995年 | 188篇 |
1994年 | 190篇 |
1993年 | 190篇 |
1992年 | 186篇 |
1991年 | 185篇 |
1990年 | 165篇 |
1989年 | 192篇 |
1988年 | 136篇 |
1987年 | 125篇 |
1986年 | 91篇 |
1985年 | 89篇 |
1984年 | 69篇 |
1983年 | 59篇 |
1982年 | 51篇 |
1981年 | 43篇 |
1980年 | 40篇 |
1979年 | 32篇 |
1978年 | 49篇 |
1977年 | 32篇 |
1976年 | 29篇 |
1974年 | 26篇 |
1973年 | 24篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Harada Hideyuki Omori Shota Mori Keita Konno Masahiro Murakami Haruyasu Imagumbai Toshiyuki Fukuda Haruyuki Nakamatsu Kiyoshi Kimura Tomoki Tanabe Hiroaki Fujita Hideki Tatebe Hitoshi Fujitaka Kazunori Nishimura Yasumasa 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(6):1025-1033
International Journal of Clinical Oncology - This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced... 相似文献
2.
Tetsuji Terazawa Takeshi Kato Masahiro Goto Katsuya Ohta Shingo Noura Hironaga Satake Yoshinori Kagawa Hisato Kawakami Hiroko Hasegawa Kazuhiro Yanagihara Tatsushi Shingai Ken Nakata Masahito Kotaka Masayuki Hiraki Ken Konishi Shiro Nakae Daisuke Sakai Yukinori Kurokawa Toshio Shimokawa Taroh Satoh 《The oncologist》2021,26(1):17-e47
Lessons Learned
- Panitumumab monotherapy showed favorable efficacy and feasibility in the treatment of frail or elderly patients with RAS wild‐type unresectable colorectal cancer.
- It is especially effective for left‐sided tumors; therefore, panitumumab as first‐line treatment could be an additional therapeutic option for frail elderly patients, particularly in those who are unsuitable for upfront oxaliplatin‐based or irinotecan‐based combination regimens.
3.
4.
5.
Yoshihiro Goto Takahiro Suzuki Yoko Suzuki Kazushi Anzawa Takashi Mochizuki Takashi Tamura Koichi Makimura Masahiro Aoshima Taisuke Ito Yoshiki Tokura 《The Journal of dermatology》2019,46(9):794-797
We report a case of kerion celsi due to Trichophyton tonsurans. An 18‐year‐old male student judo practitioner had alopecic patches, black dots and subcutaneous abscesses on the right temporal region. The damaged hair represented endothrix infection with T. tonsurans, as assessed by mycological examinations. He was treated with oral itraconazole without any therapeutic effect, followed by terbinafine with good effect. A skin biopsy showed neutrophil, lymphocyte and histiocyte infiltration into the dermis and subcutaneous tissue with abscesses around a number of dilated hair follicles. Immunostaining showed that the expression level of human β‐defensin 2 (HBD‐2) was decreased in the epidermis of the alopecic and adjacent skin. Because interleukin (IL)‐17A generally induces HBD‐2 production by epidermal keratinocytes, we also immunohistochemically investigated IL‐17A expression. Unexpectedly, many IL‐17A‐bearing cells were found around destructed hair follicles, indicating that IL‐17A expression was not attenuated, but rather increased in the skin lesion. Our case suggests that IL‐17A‐upregulated antimicrobial peptide expression is disordered in kerion celsi, and severe inflammation with IL‐17A may cause tissue damage and resultant scar. 相似文献
6.
7.
8.
Takeshi Nagashima Ken Yamaguchi Kenichi Urakami Yuji Shimoda Sumiko Ohnami Keiichi Ohshima Tomoe Tanabe Akane Naruoka Fukumi Kamada Masakuni Serizawa Keiichi Hatakeyama Kenya Matsumura Shumpei Ohnami Koji Maruyama Tohru Mochizuki Masatoshi Kusuhara Akio Shiomi Yasuhisa Ohde Masanori Terashima Katsuhiko Uesaka Tetsuro Onitsuka Seiichiro Nishimura Yasuyuki Hirashima Nakamasa Hayashi Yoshio Kiyohara Yasuhiro Tsubosa Hirohisa Katagiri Masashi Niwakawa Kaoru Takahashi Hiroya Kashiwagi Masahiro Nakagawa Yuji Ishida Takashi Sugino Mitsuru Takahashi Yasuto Akiyama 《Cancer science》2020,111(2):687-699
This study aimed to establish the Japanese Cancer Genome Atlas (JCGA) using data from fresh frozen tumor tissues obtained from 5143 Japanese cancer patients, including those with colorectal cancer (31.6%), lung cancer (16.5%), gastric cancer (10.8%) and other cancers (41.1%). The results are part of a single‐center study called “High‐tech Omics‐based Patient Evaluation” or “Project HOPE” conducted at the Shizuoka Cancer Center, Japan. All DNA samples and most RNA samples were analyzed using whole‐exome sequencing, cancer gene panel sequencing, fusion gene panel sequencing and microarray gene expression profiling, and the results were annotated using an analysis pipeline termed “Shizuoka Multi‐omics Analysis Protocol” developed in‐house. Somatic driver alterations were identified in 72.2% of samples in 362 genes (average, 2.3 driver events per sample). Actionable information on drugs that is applicable in the current clinical setting was associated with 11.3% of samples. When including those drugs that are used for investigative purposes, actionable information was assigned to 55.0% of samples. Germline analysis revealed pathogenic mutations in hereditary cancer genes in 9.2% of samples, among which 12.2% were confirmed as pathogenic mutations by confirmatory test. Pathogenic mutations associated with non–cancerous hereditary diseases were detected in 0.4% of samples. Tumor mutation burden (TMB) analysis revealed 5.4% of samples as having the hypermutator phenotype (TMB ≥ 20). Clonal hematopoiesis was observed in 8.4% of samples. Thus, the JCGA dataset and the analytical procedures constitute a fundamental resource for genomic medicine for Japanese cancer patients. 相似文献
9.
10.
Eo Toriyama Tomoko Hata Kenichi Yokota Masahiko Chiwata Rena Kamijo Miki Hashimoto Masataka Taguchi Makiko Horai Masatoshi Matsuo Emi Matsuo Yumi Takasaki Yasuhisa Kawaguchi Hidehiro Itonaga Shinya Sato Koji Ando Yasushi Sawayama Jun Taguchi Yoshitaka Imaizumi Hideki Tsushima Tatsuro Jo Shinichiro Yoshida Yukiyoshi Moriuchi Yasushi Miyazaki 《Cancer science》2020,111(12):4490
The efficacy of azacitidine (AZA) on survival of lower risk (LR) ‐ myelodysplastic syndromes (MDS) is controversial. To address this issue, we retrospectively evaluated the long‐term survival benefit of AZA for patients with LR‐MDS defined by International Prognostic Scoring System (IPSS). Using data from 489 patients with LR‐MDS in Nagasaki, hematologic responses according to International Working Group 2006 and overall survival (OS) were compared among patients that received best supportive care (BSC), immunosuppressive therapy (IST), erythropoiesis‐stimulating agents (ESA), and AZA. Patients treated with AZA showed complete remission (CR) rate at 11.3%, marrow CR at 1.9%, and any hematologic improvement at 34.0%, with transfusion independence (TI) of red blood cells in 27.3% of patients. and platelet in 20% of patients, respectively. Median OS for patients received IST, ESA, BSC, and AZA (not reached, 91 months, 58 months, and 29 months, respectively) differed significantly (P < .001). Infection‐related severe adverse events were observed in more than 20% of patients treated with AZA. Multivariate analysis showed age, sex, IPSS score at diagnosis, and transfusion dependence were significant for OS, but AZA treatment was not, which maintained even response to AZA, and IPSS risk status at AZA administration was added as factors. We could not find significant survival benefit of AZA treatment for LR‐MDS patients. 相似文献